AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$AIM

Equels Thomas K purchased $5K of AIM

Equels Thomas K (CEO & President) purchased 24,000 shares of AIM ImmunoTech Inc. (AIM) at $0.21 on 2026-09-17.

Original reporting
SEC EDGAR · Equels Thomas K
Published Sep 18, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AIM
Neutral
medium confidence
Mentioned
$AIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock significantly, but it adds a data point for monitoring insider activity.

02

Market read

Low relevance; adds a routine insider transaction to the record.

03

What to watch

Potential upcoming clinical data could make the buy more meaningful.

Relevance 4/10Novelty 4/10Timing: post-market 2026-09-17 filing

Background

SEC Form 4 filings disclose insider transactions; investors monitor them for signals of confidence.

Company-level read

Ticker impact

$AIMNeutralMedium confidence
Context

CEO Equels Thomas K purchased 24,000 shares of AIM ImmunoTech for $4,992, disclosed via SEC Form 4 on 2026-09-18.

Expected impact

Minimal short-term movement; may slightly support price.

Evidence & confidence

Purchase size is modest relative to holdings and market cap; typical for 10b5-1 plans.

Market effects

Sector

None significant for biotech sector.

Regional

No regional effect.

Global

Limited to AIM shareholders.

Counterpoint

What could challenge this read

Insider purchase may be routine; not a strong bullish signal.

Key entities

  • Individual
    Equels Thomas K

    CEO & President of AIM ImmunoTech

  • Company
    AIM ImmunoTech Inc.

    Biotech firm developing immunotherapies

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AIM insider trading history →

Related articles

AUG 10
$AIMLow

AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3…

AIM ImmunoTech Inc. (AIM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL DRAFT NOT FOR IMMEDIATE RELEASE AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen® Toward Planned Phase 3 Development in Pancreatic Cancer Completed Enrollment and Ampligen Do

SEC EDGAR 8-K2 min
JUL 23
$AIMMedAI 8/10

AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule — CEO Sees 'Significant Value-Inflection Period' Ahead

AIM ImmunoTech said its Phase 2 pancreatic cancer trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) after FOLFIRINOX reached final patient enrollment ahead of schedule. The company expects to complete dosing and assess the primary Clinical Benefit Rate endpoint in December 2026, while continuing Phase 3 planning and expanding regulatory and IP efforts.

stocktwits.com4 min
JUL 9
$AIMMed

WA gold project Warrawoona fined $118,000 over threatened bat

Australia’s DCCEEW fined AIM Mining Corporation $118,000 for EPBC breaches at its Warrawoona Gold Project in WA’s Pilbara, tied to failure to protect the threatened Pilbara leaf-nosed bat. The regulator cited groundwater extraction over limits, missing species management steps, and reporting failures. AIM said it paid the fine. Calidus previously operated the project.

abc.net.au4 min